Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study

ABSTRACT Objective To evaluate the effects of solifenacin, darifenacin, and propiverine on nasal-, subfoveal-, temporal choroidal thicknesses (NCT, SFCT, TCT), intraocular pressure (IOP) and pupil diameter (PD). Materials and Methods Patients with overactive bladder (OAB) diagnosed according to The International Continence Society were administered with solifenacin, darifenacin or propiverine on a daily basis between November 2017 and May 2018. NCT, SFCT, TCT, IOP, and PD of these patients were measured and compared as initial, fourth and twelfth weeks. Results A total of 165 patients (330 eyes) with OAB were evaluated. Solifenacin (n=140) significantly reduced IOP from 17.30±2.72 mmHg to 16.67±2.56 mmHg (p=0.006) and 16.57±2.41 mmHg (p=0.002), at the fourth and twelfth weeks, respectively. Darifenacin (n=110) significantly reduced NCT from 258.70±23.96 μm to 257.51±22.66 μm (p=0.002) and 255.36±19.69 μm (p=0.038), at the fourth and twelfth weeks, respectively. Propiverine (n=80) significantly increased PD from 4.04±0.48 mm to 4.08±0.44 mm (p=0.009) and 4.09±0.45 mm (p=0.001), at the fourth and twelfth weeks, respectively. Conclusion These findings can help to decide appropriate anticholinergic drug choice in OAB patients. We finally suggest further well-designed randomized prospective studies with a larger population to evaluate the anticholinergic-related complications in eyes.

Factors Predictive of Treatment-Emergent Adverse Events of Prucalopride: An Integrated Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials

BACKGROUND/AIMS: This integrated analysis aimed to identify the factors associated with the most frequently reported treatment-emergent adverse events (TEAEs) in Asian and non-Asian patients with chronic constipation (CC) who receive prucalopride or placebo over 12 weeks. METHODS: Pooled data from four randomized, double-blind, placebo-controlled, multicenter, phase III studies (NCT00488137, NCT00483886, NCT00485940, and NCT01116206) on patients treated with prucalopride 2 mg or placebo were analyzed. The associations between predictors and TEAEs were evaluated based on a logistic regression model. RESULTS: Overall, 1,821 patients (Asian, 26.1%; non-Asian, 73.9%) were analyzed. Prucalopride treatment was significantly associated with diarrhea, headache, and nausea (p<0.001), but not with abdominal pain, compared with placebo. Differences in the prevalence of TEAEs between prucalopride and placebo decreased greatly after the first day of treatment. Compared with non-Asians, Asians were more likely to experience diarrhea and less likely to develop abdominal pain, headache, and nausea. Prior laxative use, CC duration, and body weight were not predictive of any of these TEAEs. CONCLUSIONS: Prucalopride treatment was positively associated with diarrhea, headache, and nausea. Asian patients tended to have a higher frequency of diarrhea but lower frequencies of headache, abdominal pain, and nausea compared with non-Asians.

Factors Predictive of Treatment-Emergent Adverse Events of Prucalopride: An Integrated Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials

BACKGROUND/AIMS: This integrated analysis aimed to identify the factors associated with the most frequently reported treatment-emergent adverse events (TEAEs) in Asian and non-Asian patients with chronic constipation (CC) who receive prucalopride or placebo over 12 weeks. METHODS: Pooled data from four randomized, double-blind, placebo-controlled, multicenter, phase III studies (NCT00488137, NCT00483886, NCT00485940, and NCT01116206) on patients treated with prucalopride 2 mg or placebo were analyzed. The associations between predictors and TEAEs were evaluated based on a logistic regression model. RESULTS: Overall, 1,821 patients (Asian, 26.1%; non-Asian, 73.9%) were analyzed. Prucalopride treatment was significantly associated with diarrhea, headache, and nausea (p<0.001), but not with abdominal pain, compared with placebo. Differences in the prevalence of TEAEs between prucalopride and placebo decreased greatly after the first day of treatment. Compared with non-Asians, Asians were more likely to experience diarrhea and less likely to develop abdominal pain, headache, and nausea. Prior laxative use, CC duration, and body weight were not predictive of any of these TEAEs. CONCLUSIONS: Prucalopride treatment was positively associated with diarrhea, headache, and nausea. Asian patients tended to have a higher frequency of diarrhea but lower frequencies of headache, abdominal pain, and nausea compared with non-Asians.

Hidrocarburos aromáticos policíclicos: riesgos para la salud y marcadores biológicos / Policíclicos aromatic hydrocarbons: biological risks for the health and markers

El objetivo del presente trabajo fue investigar los efectos de la anestesia con Enflurano e Isoflurano en ratones con niveles hepáticos de citocromo P-450 (CYP) disminuidos o aumentados. Los animales previamente tratados con alilisopropil-acetamida(AIA) (350 mg/Kg), agente destructor del CYP o con Imidazol (400 mg/Kg) como inductor, recibieron una única dosis de los anestésicos ( 1mL/Kg). En el grupo que recibió AIA, los niveles de CYP permanecieron reducidos aún después de la anestesia. Sin embargo, los anestésicos revirtieron el aumento del CYP provocado por Imidazol. La actividad de la isoforma CYP2E1 se indujo en los grupos que recibieron los anestésicos, siendo mayor por la acción conjunta de imidazol y Enflurano, esto indicaría un aumento en la metabolización de este anestésico. En Animales tratados con Imidazol, el Isoflurano revirtió parcaialmente la inhibición de las actividades de B-glucuronidasa y sulfatasa producidas por dicho xenobiótico. Ambos anestésicos causaron una reducción en la actividad de triptofano pirrolasa en el grupo que recibió Imidazol pero no en los tratados con AIA. En conclusión, la acción de los anestésicos Enflurano e Isoflurano sobre el sistema metabolizante de drogas dependería de que el CYP esté inducido o no y del anestésico estudiado a pesar de su similitud estructural.

Experiencia clínica con amiodarona / Clinical experience with amiodarone

Se utilizó la amiodarona en 80 pacientes con síntomas por taquiarritmias rebeldes. Fue efectiva en el 72,2% de los 44 pacientes con taquiarritmias supraventriculares y en el 86,1% de los que sufrían por arritmias ventriculares. Estos pacientes se siguieron durante 18 meses, aunque en 9 no se completó el tiempo de observación. El tiempo medio de comienzo de la efectividad de la droga fue de 7,5 días. Se sugiere que los microputeados en la córnea que comenzaron a detectarse a partir de los primeros 15 días del tratamiento pueden considerarse como un signo de impregnación del medicamento. Se recomienda el empleo de este fármaco en pacientes cuyo tratamiento con otras drogas antiarrítmicas haya fracasado, pues a pesar de su eficacia puede ocasionar diversas reacciones indeseables